The review of the Voluntary Scheme for Branded Medicines Pricing and Access (VPAG), expected in Autumn 2025, has been brought forward and is due to conclude at the end of June 2025.
The Charities Medicines Access Coalition (CMAC), a coalition of 26 health charities representing millions of patients across the UK, is calling for the Government and the pharmaceutical industry to be more transparent and share clear evidence that patient impact is at the heart of the ongoing VPAG discussions and negotiations.
- The Government must ensure all options being discussed for reform within the VPAG scheme are formally assessed for their impact on NHS patients.
- The Government and the pharmaceutical industry must also increase their communication and open meaningful discussions with patient organisations within this review.
This statement is supported by the following CMAC members: Action Bladder, Action for Pulmonary Fibrosis, Alzheimer’s Research UK, Breast Cancer Now, Blood Cancer Alliance, The Brain Tumour Charity, Brain Tumour Research, Cancer Research UK, Cancer 52, Cardiomyopathy UK, Cystic Fibrosis Trust, Diabetes UK, Genetic Alliance UK, JDRF UK, Kidney Research UK, Leukaemia UK, Make 2nds count, METUP UK, MNDA Association, MS Society, Myeloma UK, Neurological Alliance, Prostate Cancer UK, Retina UK, SmellTaste, Spinal Muscular Atrophy UK.
